文献速递肝病

乙酰辅酶A羧化酶抑制可逆转NAFLD和肝脏胰岛素抵抗但促进啮齿类动物高甘油三酯血症

Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
PubMed 文献 · Hepatology · 2018-01-01

研究在饮食诱导的NAFLD啮齿类模型中评估肝脏定向ACC1/ACC2变构抑制剂(化合物1)的效果,发现其抑制肝脏ACC活性、降低丙二酰辅酶A、增强生酮50%,21天治疗显著减少肝脂肪变性和肝脏胰岛素抵抗,但血浆甘油三酯升高约30%至130%,该高甘油三酯血症可被非诺贝特逆转。

要点

  • 化合物1口服优先抑制肝脏ACC活性并降低肝脏丙二酰辅酶A水平。
  • 21天治疗显著减少高脂蔗糖饮食诱导的肝脂肪变性和肝脏胰岛素抵抗。
  • ACC抑制相关高甘油三酯血症可被非诺贝特联合治疗逆转。

核心结论

  • 这些研究提示需进一步研究肝脏定向ACC抑制治疗NAFLD和肝脏胰岛素抵抗的治疗用途。

研究设计与样本

  • 在对照和饮食诱导的NAFLD啮齿类模型中评估肝脏定向ACC1和ACC2变构抑制剂(化合物1)对肝脏线粒体氧化、回补和生酮以及糖脂代谢的影响。

主要发现

  • 口服化合物1优先抑制肝脏ACC酶活性、降低肝脏丙二酰辅酶A水平并使肝脏生酮增强50%。
  • 高果糖喂养大鼠给药6天使肝脏从头脂肪合成减少20%。
  • 长期治疗21天显著减少高脂蔗糖饮食诱导的肝脂肪变性、蛋白激酶Cε激活和肝脏胰岛素抵抗。
  • ACC抑制治疗与血浆甘油三酯显著升高相关(约30%至130%,取决于禁食时间长短)。
  • ACC抑制介导的高甘油三酯血症可归因于肝脏极低密度脂蛋白生成增加约15%和脂蛋白脂肪酶对甘油三酯清除减少约20%(P≤0.05)。

关键数值与推荐

  • 分子水平上这些变化与肝X受体/固醇调节元件结合蛋白-1增加和过氧化物酶体增殖物激活受体-α靶基因激活减少相关,在高脂饮食小鼠模型中可被非诺贝特联合治疗逆转。

局限性

  • 原文结论指出这些研究需要进一步研究肝脏定向ACC抑制治疗NAFLD和肝脏胰岛素抵抗的治疗用途。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacologic inhibition of acetyl-CoA carboxylase (ACC) enzymes, ACC1 and ACC2, offers an attractive therapeutic strategy for nonalcoholic fatty liver disease (NAFLD) through simultaneous inhibition of fatty acid synthesis and stimulation of fatty acid oxidation. However, the effects of ACC inhibition on hepatic mitochondrial oxidation, anaplerosis, and ketogenesis in vivo are unknown. Here, we evaluated the effect of a liver-directed allosteric inhibitor of ACC1 and ACC2 (Compound 1) on these parameters, as well as glucose and lipid metabolism, in control and diet-induced rodent models of NAFLD. Oral administration of Compound 1 preferentially inhibited ACC enzymatic activity in the liver, reduced hepatic malonyl-CoA levels, and enhanced hepatic ketogenesis by 50%. Furthermore, administration for 6 days to high-fructose-fed rats resulted in a 20% reduction in hepatic de novo lipogenesis. Importantly, long-term treatment (21 days) significantly reduced high-fat sucrose diet-induced hepatic steatosis, protein kinase C epsilon activation, and hepatic insulin resistance. ACCi treatment was associated with a significant increase in plasma triglycerides (approximately 30% to 130%, depending on the length of fasting). ACCi-mediated hypertriglyceridemia could be attributed to approximately a 15% increase in hepatic very low-density lipoprotein production and approximately a 20% reduction in triglyceride clearance by lipoprotein lipase (P ≤ 0.05). At the molecular level, these changes were associated with increases in liver X receptor/sterol response element-binding protein-1 and decreases in peroxisome proliferator-activated receptor-α target activation and could be reversed with fenofibrate co-treatment in a high-fat diet mouse model. Conclusion: Collectively, these studies warrant further investigation into the therapeutic utility of liver-directed ACC inhibition for the treatment of NAFLD and hepatic insulin resistance.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Goedeke L, Bates J, Vatner DF, et al. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. Hepatology. 2018. PMID: 29790582. doi:10.1002/hep.30097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。